ARTELO BIOSCIENCES ARTL 深 沪
已收盘 10-10 16:00:00 美东时间
4.51
-0.340
-7.01%
华盛通- 最 高4.87
- 今 开4.85
- 成交量 5.79万股
- 最 低 4.40
- 昨 收 4.85
- 总市值 246.61万
- 52周最高 28.60
- 市盈率 静 --
- 换手率 10.59%
- 52周最低 4.20
- 委 比 96.15%
- 总股本 54.68万
- 历史最高 450.00
- 量 比 1.02
- 振 幅 9.69%
- 历史最低 4.40
- 每 手 1
- 风险率 0.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Artelo Biosciences Prices $2.0M Public Offering
SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for
09-30 22:11
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers SciSparc (NASDAQ:SPRC) stock increased by 40.8% to $6.28 during Tuesda...
09-30 20:09
Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference
.Artelo Biosciences announced interim data from its Phase 2 CAReS study showing that ART27.13, a novel cannabinoid agonist, significantly improved weight, lean body mass, and daily activity in patients with cancer anorexia-cachexia syndrome (CACS). Patients on the highest dose (1300 µg) achieved a 6% weight gain over 12 weeks, while those on placebo lost an additional 5%. ART27.13 demonstrated a favorable safety profile, with mostly mild to moder...
09-29 12:30
Artelo Biosciences Completes Stock Offering with Over-Allotment
Artelo Biosciences ( ($ARTL) ) has provided an update. Artelo Biosciences, Inc....
09-16 04:57
Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms
Artelo Biosciences announced the publication of new preclinical data on ART12.11, its CBD:TMP cocrystal. The study, conducted with Western Ontario University, showed ART12.11 significantly outperformed CBD alone in reducing stress-induced depression and anxiety symptoms and achieved superior oral bioavailability. Key findings include enhanced efficacy, improved bioavailability, and mechanistic insights into its effects on endocannabinoid and sero...
09-10 12:30
D. Boral Capital Downgrades Artelo Biosciences to Hold
D. Boral Capital analyst Jason Kolbert downgrades Artelo Biosciences (NASDAQ:ARTL) from Buy to Hold.
09-08 19:21
Artelo Biosciences Announces Pricing of $3.0 Million Public Offering
Artelo Biosciences, a clinical-stage pharmaceutical company, has priced its public offering of 640,924 shares of common stock at $4.40 per share and pre-funded warrants for up to 40,894 shares at $4.399 per warrant. The offering is expected to raise approximately $3.0 million in gross proceeds. Underwriters have a 45-day option to purchase an additional 102,272 shares. The offering is expected to close on September 5, 2025, subject to customary c...
09-04 12:37
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Biodesix (NASDAQ:BDSX) shares increased by 21.6% to $0.52 during Wedne...
09-04 05:06
Artelo Biosciences launches public offering; shares down 10%
Artelo Biosciences (NASDAQ:ARTL) has commenced an underwritten public offering of common stock and/or pre-funded warrants. All securities in the offering will be sold by the company itself. The size, ...
09-04 04:50
Artelo Biosciences Announces Interim Results From Phase 2 CAReS Trial With ART27.13, Peripherally Acting Cannabinoid Receptor Agonist For Treatment Of CACS
Catalyst for Advancing Discussions with Pharmaceutical Companies that have Expressed Interest in ART27.13 for CACSConsistent Improvements in Weight Gain, Lean Body Mass, and Activity were Observed Across Treated Patients
09-03 20:47
